Why Recursion Pharmaceuticals Stock Is Sinking Today

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...
AOL

Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Nasdaq

Recursion to Present Preliminary Data on REC-4881 for Familial Adenomatous Polyposis at ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...
The Motley Fool

Is Recursion Pharmaceuticals a Millionaire Maker?

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...